One year round up – what we’ve been up to in our first year
The 1st September 2019 officially marks the one year anniversary of the launch of TherapeutAix – and what an exciting…
TherapeutAix to attend the ‘New Targets & Modalities in Fibrosis’ ELRIG Networking event on the 18th September
Held in Oxford on September 18th, this ELRIG event will look at what researchers are doing to support patients with…
International NASH Day 2019
On International NASH Day 2019 we discuss the mixed outcomes of NASH drug clinical trials and how we believe a…
TherapeutAix adds Immunoconsulting to global R&D Network
We are pleased to announce that we have grown our global R&D Network with the addition of ImmunoConsulting Ltd. ImmunoConsulting,…
Recent study highlights the challenges in developing treatments for NASH
We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated…
